Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

HMG Dosage Protocol | PeptideDosages.com

HMG (0.15 mg / 75 IU Vial) Dosage Protocol HMG Dosage Chart HMG is dosed at 75 IU weekly via subcutaneous injection in educational protocols. Reconstitute the 0.15 mg / 75 IU vial with bacteriostatic water before use. This information is for research and educa

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

HMG (0.15 mg / 75 IU Vial) Dosage Protocol

HMG Dosage Chart

HMG is dosed at 75 IU weekly via subcutaneous injection in educational protocols. Reconstitute the 0.15 mg / 75 IU vial with bacteriostatic water before use. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → 25 IU/mL concentration.

Typical protocol: 75 IU three times weekly for 12–16 weeks, usually combined with hCG therapy.

Volume consideration: Each 75 IU dose = 3.0 mL, requiring a 3 mL syringe or multiple 1 mL injections.

Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, use promptly or refrigerate and use within a few days.

Human Menopausal Gonadotropin (HMG) is a purified gonadotropin preparation containing equal amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity[1][2]. In males, HMG is used alongside hCG to stimulate spermatogenesis in cases of hypogonadotropic hypogonadism or infertility[3][4]. This educational protocol presents a thrice-weekly subcutaneous approach for male fertility support.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read HMG Peptide: Human Menopausal Gonadotropin, Dosage, IU, Side Effects, and Research.

Male Fertility Protocol (3 mL = 25 IU/mL)

Weeks 1–12

75 IU (0.15 mg)

3.0 mL (300 units)

Weeks 13–16 (optional extension)

Frequency: Inject three times per week subcutaneously (for example, Monday, Wednesday, and Friday)[3][4]. HMG therapy is typically combined with hCG injections to maximize testosterone production and spermatogenesis[5][6].

Important Volume Note: Each full 75 IU dose requires 3.0 mL, which exceeds standard 1 mL insulin syringe capacity. Options include:

Use a 3 mL syringe (preferred for single injection)

Split dose into three 1 mL injections at different sites (1 mL = 25 IU each)

Consider smaller reconstitution volume (1 mL) per manufacturer guidance for reduced injection volume[8]

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile 3 mL syringe.

Inject slowly down the vial wall to avoid foaming.

Gently swirl or roll the vial until fully dissolved (do not shake).

Label with date and time; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

For optimal potency, use reconstituted solution promptly or within a few days[9].

Supplies Needed

Plan based on a 12–16 week male fertility protocol with thrice-weekly administration.

Peptide Vials (HMG, 75 IU / 0.15 mg each):

12 weeks ≈ 36 vials (3 per week × 12 weeks)

16 weeks ≈ 48 vials (3 per week × 16 weeks)

Syringes (3 mL):

Per week: 3 syringes (one per injection)

12 weeks: 36 syringes

16 weeks: 48 syringes

Note: If using 1 mL insulin syringes, multiply counts by 3 for split-dose administration.

Bacteriostatic Water (30 mL bottles): Use 3.0 mL per vial for reconstitution.

12 weeks (36 vials): 108 mL → 4 × 30 mL bottles

16 weeks (48 vials): 144 mL → 5 × 30 mL bottles

Alcohol Swabs: One for the vial stopper + one for each injection site.

Per week: 6 swabs (2 per injection day)

12 weeks: 72 swabs → recommend 1 × 100-count box

16 weeks: 96 swabs → recommend 1 × 100-count box

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Humanin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Humanin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03AHK-Cu — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. AHK-Cu is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Retinalamin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Retinalamin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Human SNAP-8 Research Formulations

Human evidence is topical or device-assisted. Conventional cream data come from ingredient-developer testing. Peer-reviewed studies used multi-active serums or dissolving microneedle patches, so their outcomes cannot be assigned to SNAP-8 alone. Lipotec developer panel[6] Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide Twice daily around the eye area for 28 days 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported Manufacturer-reported, not an independent peer-reviewed trial Shin et al. (2024)[1] 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA Overnight nightly through day 14, then every third day through day 28 24 enrolled and 21 completed a split-face active-versus-placebo comparison Combination device; SNAP-8’s independent contribution cannot be isolated Avcil et al. (2020)[2] HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts 12-week study Fine lines, hydration, dermal density, thickness, and tolerability measures Multi-active product; SNAP-8 concentration was not disclosed in the abstract Draelos et al. (2016)[3] Multi-peptide serum containing SNAP-8 within a supporting skincare regimen Morning and evening for 12 weeks after a 2-week washout 29 women; investigator grading and participant questionnaires Open label, no control, multiple peptides and supporting products Moy et al. (2023)[4] Proprietary multi-peptide facial serum containing acetyl octapeptide-3 Twice daily for 12 weeks 31 women completed dermatologist grading, imaging, hydration, and questionnaires Uncontrolled, multi-ingredient, and company funded

Source: peptidedosages.com ↗

Safety and Tolerability in the Research Setting

Safety and efficacy are separate questions, and it is entirely possible for a compound to be well tolerated while remaining unproven for the condition of interest. That is the current situation for NAD+ precursors in Parkinson’s disease. The short-term tolerability data, particularly for oral nicotinamide riboside, are reassuring within the limits of the trials conducted, but they are not a statement about long-term safety, about frail or elderly populations over years, or about drug interactions in people taking multiple Parkinson’s medications. The most directly relevant safety dataset is NR-SAFE, which was explicitly designed to probe tolerability at a high dose. Over four weeks, 3,000 mg of NR daily produced only mild adverse events, with no moderate or severe events and no significant excess over placebo; the most frequently reported events in the NR arm included extrapyramidal symptoms, headache, tremor, muscle cramps, fatigue, nausea, and dyspepsia, several of which overlap with the underlying disease and its treatment.2 The absence of painful flushing is notable because flushing is a classic dose-limiting effect of nicotinic acid (niacin); NR and nicotinamide generally avoid the flushing that niacin causes, which is one reason they are favored for chronic dosing. The lower-dose NADPARK trial similarly reported that 1,000 mg daily was well tolerated over 30 days.1 Broader supplement-safety literature on NR in non-Parkinson populations has generally supported tolerability at commonly studied doses, and NMN has likewise been reported to raise blood NAD+ safely in short studies of healthy adults.13 These reassurances come with substantial caveats that a careful reader should hold in mind. First, the trials are small and short. Twenty participants over four weeks, or thirty over one month, cannot detect uncommon adverse events or effects that only emerge with months to years of exposure, which is exactly the exposure that disease modification would require. Second, the populations were selected: early-stage, often newly diagnosed patients able to participate in a trial, not the full spectrum of advanced disease, multimorbidity, and polypharmacy seen in practice. Third, theoretical concerns exist that have not been resolved in humans. Because NAD+ metabolism intersects with cell proliferation and with the kynurenine pathway, and because some preclinical work has raised tissue-specific concerns about chronic high-dose precursor exposure (for example, questions about metabolite accumulation with sustained oral NMN in animal models), long-term safety cannot be assumed from short-term tolerability.13 Fourth, methylation load is a plausible consideration: clearance of excess nicotinamide consumes methyl groups, and the metabolic consequences of chronically high precursor intake over years are not well characterized in this population. There is also the matter of source and quality. In a research context, the identity, purity, and endotoxin status of a compound materially affect both the validity of an experiment and the safety of any handling. Injectable NAD+ preparations used outside regulated trials vary widely in provenance, and intravenous NAD+ administration in particular has been associated with infusion-related discomfort (nausea, chest tightness, flushing) that is typically managed by slowing the infusion rate but underscores that route and formulation matter.4 None of this constitutes clinical guidance. The appropriate summary is that oral NR appears well tolerated in the short term at the doses tested in early Parkinson’s trials, that other precursors and routes have thinner safety records, and that long-term safety in Parkinson’s disease specifically remains unestablished pending completed, published, adequately long trials.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

DSIP (5mg Vial) Dosage Protocol

Delta Sleep-Inducing Peptide — experimental, unapproved research peptide; no standardized dosing.

Source: dosagepeptide.com ↗
Storage reference

Storage Instructions

Proper storage preserves compound stability. Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4]. Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks. Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues. Do not refreeze reconstituted solution.

Source: peptidedosages.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →